Tenon Medical, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2024, on March 20, 2025. The company achieved full year 2024 revenue of $3.3 million, representing a 12% increase compared to the prior year.
For the fourth quarter of 2024, revenue stood at $0.8 million, which was in line with the fourth quarter of 2023. The company also highlighted that an interim analysis from its MAINSAIL study reinforced the safety profile, effectiveness, and confirmation of fusion for its Catamaran system.
Further strategic updates included the protection of Catamaran SI Joint Fusion Technology with a robust patent portfolio of twelve U.S. and international patents. Tenon Medical also introduced its Catamaran SE platform, successfully completed initial clinical procedures, and projected a national commercial launch for Catamaran SE in mid-2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.